The Cannabinoid Family, Molecule by Molecule

One name, many molecules

A cannabinoid is a member of one chemical family. Most people meet that family through hemp, where the plant builds these compounds into its resin. The rest of the family is made inside the human body, which produces structurally related molecules of its own. Same family. Two very different addresses.

Hemp doesn't make one cannabinoid. It makes many. When ElSohly and Slade reviewed the chemical constituents of the plant in 2005, they described its cannabinoid content as a complex mixture rather than a short list of famous initials [1]. That is the first useful thing to know here: the names everyone recognises are entries in a much longer catalogue.

The initials get simpler once you unpack them. CBD is cannabidiol. CBG is cannabigerol. CBN is cannabinol. THC is tetrahydrocannabinol. An added a or A, as in CBDa or CBGA, marks an acid form, and acid forms are what a living plant actually accumulates. Heat and time convert them into the neutral forms that most labels and batch reports list. Three letters on a bottle are shorthand for a whole branch of plant chemistry.

So the map has three layers worth keeping apart: what the plant makes in acid form, what those acids turn into, and what the body produces without any plant involved. Most conversations about cannabinoids collapse all three into one, and that is usually where the confusion starts.

THC sits on the map too, and here it stays on the map rather than in the bottle. Our formulas are non-intoxicating and within legal limits, and every batch is analysed so the figures can be read before anything is opened.

Cibdol has been working with cannabinoids since 2014, starting with CBD. CBG and CBN came later, once the evidence and our own extraction work caught up with them. That order matters more than it sounds. A compound reaches a bottle here after it can be measured reliably, not because its initials are having a moment.

Reading the map by group

Groups first, individual molecules second. Cannabinoids from the plant are one group. Cannabinoids made in the body are another. The two share a chemical logic and little else: one arrives through extraction, the other is produced inside human tissue.

Within the plant group, the split that matters most is acid versus neutral. Cannabigerolic acid, CBGA, is the compound Fellermeier and Zenk pinned down in 1998, when they described a hemp transferase attaching a prenyl group to olivetolate and identified the product as the precursor of tetrahydrocannabinol [2]. The plant's chemistry runs as a sequence, not a scatter of unrelated molecules.

Abundance is the other axis. Some cannabinoids show up in percentages, others in traces. CBN is the clear example: a 2019 cannabis report lists it among the constituents present in very small amounts, which is one reason work on it stayed thin for years. Keeping those two axes in mind, the family looks like this:

• Acid forms. What the plant accumulates while it is alive, written with an a or A: CBGA, CBDa and their relatives.
• Neutral forms. CBD, CBG, CBN and THC, the versions that dominate ingredient lists and lab analyses after heat and time have done their part.
• The named precursor. Cannabigerolic acid, described in 1998 by Fellermeier and Zenk as the compound standing ahead of tetrahydrocannabinol [2].
• The trace entries. CBN among them, recorded in very small amounts in a 2019 cannabis report, which makes it a manufacturing question as much as a botanical one.
• The body's own pair. Anandamide and 2-arachidonoylglycerol, better known as 2-AG, produced internally rather than harvested.
• The catalogue as a whole. Reviewed by ElSohly and Slade in 2005 as a complex mixture rather than a handful of compounds [1].
• Our shelf. CBD from 2014 onwards, with CBG and CBN added as separate lines later.

Where the plant's sequence begins

A hemp enzyme and a prenyl group

Chemistry, told slowly. In 1998, Fellermeier and Zenk worked with a transferase from hemp, an enzyme whose job is to move one molecular part onto another. The part being moved was a prenyl group. The molecule receiving it was olivetolate. The product of that transfer was cannabigerolic acid [2]. One enzyme, one attachment step, one new acid.

It is a small piece of biochemistry, and it explains the shape of the whole family. Cannabinoids aren't built independently of one another, one per name. They come out of a sequence, and that sequence has a starting point with an address and a date in the literature.

The acid that comes before THC

Fellermeier and Zenk described cannabigerolic acid specifically as the precursor of tetrahydrocannabinol [2]. Precursor is the plain word for it: the compound that comes first and gets converted into something later. In that account the acid is the earlier molecule, THC the downstream one.

Read next to the 2005 review, the picture stops looking like a menu of separate ingredients. ElSohly and Slade catalogued the plant's constituents as a complex mixture [1], which is what you would expect from chemistry that branches out of a shared starting material rather than assembling each compound from scratch.

This is also the practical reason we analyse every batch. Plants don't run the same sequence to the same endpoint every harvest, and a printed figure is the only version of a cannabinoid profile you can actually check. Hemp chemistry explains the range. The report tells you where a specific bottle landed inside it.

The cannabinoids your body makes

Anandamide and 2-AG

Two names sit at the centre of the endogenous side. Anandamide is one. 2-arachidonoylglycerol, almost always shortened to 2-AG, is the other. It is described as the second principal endocannabinoid, and it is usually the more abundant of the pair. It doesn't occur in cannabis at all: the body produces it.

Together, those two molecules give the endocannabinoid system its name. We keep separate pages for the system, for anandamide and for 2-AG, because each one carries more detail than a family map can hold, and that is the order to read them in if this section left you curious.

CBD first, then CBG and CBN

Our own cannabinoid work started in 2014 with CBD. CBG and CBN followed, and only when two things lined up: published evidence worth writing about, and extraction consistent enough to put a number on a label and stand behind it.

That is why the shelf here is shorter than the catalogue. Hemp holds a complex mixture [1]; a product range should hold what can be isolated, measured and repeated. CBN shows why the gap exists, since a 2019 cannabis report places it in very small amounts, so concentrating it is an extraction problem long before it becomes a product. Our CBN page sets out where the research currently stands and where it stays open.

Since 2014, one standard: know what's inside. The batch analysis is where you check that the map and the bottle agree.